Differential dignosis: „primary“ or secondary diabetes – should Cushing´s syndrome be routinely screened in the patients with type 2 diabetes mellitus?

Česká verzia

Authors: Karolína Melicharová ¹; Ludmila Brunerová ²; Jana Urbanová ²; Jan Brož ¹
Authors place of work: Interní klinika FN Motol a 2. LF UK, Praha ¹; Interní klinika FNKV a 3. LF UK, Praha ²
Published in the journal: Vnitř Lék 2021; 67(E-3): 8-10
Category: Review Articles

Summary

Cushing´s syndrome is a rare disease with the population prevalence about 40 patients per 1 million inhabitants, the number among patients with diabetes mellitus (DM) is probably higher. The screening of CS among the DM patients showed the prevalence between 0–2.9% in the groups of outpatients and 2–2.9% among the patients admitted to the hospital at the time of randomization. The routine screening of CS among patients with type 2 DM is not recommended at the moment. Nevertheless, the possibility of CS should be taken into the account mainly in patients with hypertension, obesity, microvascular complications, bad level of metabolic control or high insulin doses, especially, if more of these features are present. A hormonal profile of patients with adrenal incidentaloma should be evaluated.

Keywords:

Cushing´s syndrom – diabetes mellitus – screning – adrenal incidentaloma

Zdroje

1. Kršek M. Cushingův syndrom. 2013; Interní medicína pro praxi 2013; 15: 368–371.

2. Lynnette K. Nieman, Beverly M. K. Biller, James W. Findling, John Newell-Price, Martin O. Savage, Paul M. Stewart, Victor M. Montori, The Diagnosis of Cushing‘s Syndrome: An Endocrine Society Clinical Practice Guideline, JCEM 2008; 93(5): 1526–1540. https://doi. org/10.1210/jc.2008-0125.

3. Hsieh LB, Mackinney E, Wang TS. When to Intervene for Subclinical Cushing‘s Syndrome. Surg Clin North Am. 2019; 99(4): 747–758.

4. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing‘s syndrome. Lancet. 2015; 386: 913–927.

5. Castinetti F, Morange I, Conte-Devolx B, Brue T. Cushing‘s disease. Orphanet J Rare Dis. 2012; 7: 41.

6. Rubinstein G, Osswald A, Hoster E et al. Time to Diagnosis in Cushing‘s Syndrome: A Meta-Analysis Based on 5367 Patients. J Clin Endocrinol Metab. 2020; 105(3): dgz136.

7. Javanmard P, Duan D, Geer EB. Mortality in Patients with Endogenous Cushing‘s Syndrome. Endocrinol Metab Clin North Am. 2018; 47(2): 313–333.

8. Petramala L, Olmati F, Concistrè A, et al. Cardiovascular and metabolic risk factors in patients with subclinical Cushing [published online ahead of print, 2020 Apr 16]. Endocrine. 2020;10.1007/s12020-020-02297-2. doi:10.1007/s12020-020-02297-2.

9. Barbot M, Ceccato F, Scaroni C. Diabetes Mellitus Secondary to Cushing‘s Disease. Front Endocrinol (Lausanne). 2018; 9: 284.

10. Kršek M. Poruchy metabolizmu cukrů u Cushingova syndromu. Forum Diabetologicum. 2014; 3: 123–127.

11. Cansu GB, Atılgan S, Balci MK et al. Which type 2 diabetes mellitus patients should be screened for subclinical Cushing‘s syndrome? Hormones (Athens). 2017; 16: 22–32.

12. Chiodini I, Torlontano M, Scillitani A et al. Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients. Eur J Endocrinol. 2005; 153: 837–844.

13. Gungunes A, Sahin M, Demirci T et al. Cushing‘s syndrome in type 2 diabetes patients with poor glycemic control. Endocrine. 2014; 47: 895–900.

14. Reimondo G, Castellano E, Grosso M et al. Adrenal Incidentalomas are Tied to Increased Risk of Diabetes: Findings from a Prospective Study. J Clin Endocrinol Metab. 2020; 105(4): dgz284.